GB2600026B - Intranasal epinephrine formulations and methods for the treatment of disease - Google Patents

Intranasal epinephrine formulations and methods for the treatment of disease Download PDF

Info

Publication number
GB2600026B
GB2600026B GB2117505.4A GB202117505A GB2600026B GB 2600026 B GB2600026 B GB 2600026B GB 202117505 A GB202117505 A GB 202117505A GB 2600026 B GB2600026 B GB 2600026B
Authority
GB
United Kingdom
Prior art keywords
disease
treatment
methods
epinephrine formulations
intranasal epinephrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2117505.4A
Other languages
English (en)
Other versions
GB202117505D0 (en
GB2600026A (en
Inventor
Lowenthal Richard
T Maggio Edward
G Bell Robert
Shah Pratik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aegis Therapeutics LLC
ARS Pharmaceuticals Inc
Original Assignee
Aegis Therapeutics LLC
ARS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68593261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2600026(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US15/890,131 external-priority patent/US10576156B2/en
Application filed by Aegis Therapeutics LLC, ARS Pharmaceuticals Inc filed Critical Aegis Therapeutics LLC
Publication of GB202117505D0 publication Critical patent/GB202117505D0/en
Publication of GB2600026A publication Critical patent/GB2600026A/en
Application granted granted Critical
Publication of GB2600026B publication Critical patent/GB2600026B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB2117505.4A 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease Active GB2600026B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/890,131 US10576156B2 (en) 2004-08-25 2018-02-06 Compositions for drug administration
US201862685049P 2018-06-14 2018-06-14
US201862734550P 2018-09-21 2018-09-21
US201862784057P 2018-12-21 2018-12-21
GB2016960.3A GB2587934B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease

Publications (3)

Publication Number Publication Date
GB202117505D0 GB202117505D0 (en) 2022-01-19
GB2600026A GB2600026A (en) 2022-04-20
GB2600026B true GB2600026B (en) 2022-10-12

Family

ID=68593261

Family Applications (3)

Application Number Title Priority Date Filing Date
GB2016960.3A Active GB2587934B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease
GB2012086.1A Active GB2583051B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease
GB2117505.4A Active GB2600026B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB2016960.3A Active GB2587934B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease
GB2012086.1A Active GB2583051B (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease

Country Status (22)

Country Link
EP (2) EP4169511A1 (de)
KR (3) KR20220035512A (de)
CN (2) CN110505873B (de)
AU (3) AU2019217643B2 (de)
BR (1) BR112020015646A2 (de)
CA (1) CA3088989C (de)
CY (1) CY1125856T1 (de)
DE (1) DE112019000683T5 (de)
ES (2) ES2791775B2 (de)
FI (1) FI3678649T3 (de)
GB (3) GB2587934B (de)
HR (1) HRP20221525T1 (de)
HU (1) HUE060917T2 (de)
IL (1) IL276485B1 (de)
LT (1) LT3678649T (de)
MA (1) MA50106A (de)
MX (2) MX2020008132A (de)
PL (1) PL3678649T3 (de)
PT (1) PT3678649T (de)
RS (1) RS63866B1 (de)
SG (1) SG11202007527XA (de)
SI (1) SI3678649T1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127020A1 (en) * 2013-02-12 2014-08-21 Ys Pharmtech Epinephrine formulations for medicinal products
US20170216199A1 (en) * 2015-09-18 2017-08-03 Insys Development Company, Inc. Epinephrine spray formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2011139838A2 (en) * 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127020A1 (en) * 2013-02-12 2014-08-21 Ys Pharmtech Epinephrine formulations for medicinal products
US20170216199A1 (en) * 2015-09-18 2017-08-03 Insys Development Company, Inc. Epinephrine spray formulations

Also Published As

Publication number Publication date
CN116549389A (zh) 2023-08-08
DE112019000683T5 (de) 2020-10-15
HRP20221525T1 (hr) 2023-03-03
HUE060917T2 (hu) 2023-04-28
GB2583051A (en) 2020-10-14
GB202016960D0 (en) 2020-12-09
RS63866B1 (sr) 2023-01-31
EP4169511A1 (de) 2023-04-26
AU2021254650A1 (en) 2021-11-18
GB202117505D0 (en) 2022-01-19
BR112020015646A2 (pt) 2020-12-08
EP3678649B8 (de) 2022-11-16
SI3678649T1 (sl) 2023-04-28
FI3678649T3 (fi) 2023-01-31
ES2791775A2 (es) 2020-11-05
KR20200121818A (ko) 2020-10-26
MX2020008132A (es) 2020-11-18
PT3678649T (pt) 2023-01-16
CA3088989C (en) 2023-03-07
CN110505873B (zh) 2022-12-30
MA50106A (fr) 2021-04-21
IL276485B1 (en) 2024-08-01
KR20240019858A (ko) 2024-02-14
CN110505873A (zh) 2019-11-26
ES2935684T3 (es) 2023-03-09
KR20220035512A (ko) 2022-03-22
PL3678649T3 (pl) 2023-05-08
IL276485A (en) 2020-09-30
LT3678649T (lt) 2023-02-10
AU2024201523A1 (en) 2024-03-28
AU2021254650B2 (en) 2024-02-22
KR102375232B1 (ko) 2022-03-16
GB2587934A (en) 2021-04-14
CA3088989A1 (en) 2019-08-15
EP3678649B1 (de) 2022-10-26
GB2587934B (en) 2022-01-19
AU2019217643B2 (en) 2021-10-28
EP3678649A4 (de) 2020-10-14
GB202012086D0 (en) 2020-09-16
GB2583051B (en) 2020-12-02
CY1125856T1 (el) 2024-09-20
SG11202007527XA (en) 2020-09-29
MX2023002506A (es) 2023-03-13
ES2791775R1 (es) 2021-07-02
ES2791775B2 (es) 2023-01-20
EP3678649A1 (de) 2020-07-15
GB2600026A (en) 2022-04-20
AU2019217643A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL269174A (en) Methods for treating binding-mediated diseases or disorders
IL266047A (en) Methods and preparations for the treatment of Fabry disease
IL284414A (en) Methods and preparations for the treatment of Fabry disease
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
IL283948A (en) Methods for treating depression
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL272937A (en) Preparations and methods for the treatment of diseases involving fibrosis
IL283782A (en) Analosomes and methods of use
IL276053A (en) Therapeutic Gard and methods of its use
EP3258930A4 (de) Oxabicycloheptane und oxabicycloheptene zur behandlung von depressiven und stressbedingten störungen
EP3796928A4 (de) Behandlung von morbus gaucher
EP3755148A4 (de) Nanosuspensionen von salsaten und verwendungsverfahren dafür
GB201812324D0 (en) Near-infraed chromophores, process of preparation and methods of use
EP3538083A4 (de) Formulierungen zur behandlung von erkrankungen der augenoberfläche und zugehörige verfahren
IL276485A (en) Intrathecal epinephrine formulations and methods for treating the disease
IL282685A (en) Methods for treatment using anti-CD123 immunoconjugates
EP3585411A4 (de) Il-22bp-zusammensetzungen und verfahren zur behandlung von krankheiten damit
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
GB201818904D0 (en) New formulations and methods
IL268844A (en) Peptides and methods of treating dystrophy-related diseases by them
AU2017904032A0 (en) Implants for the Treatment of Diseases and Disorders
AU2016904007A0 (en) Implants for the Treatment of Diseases and Disorders
AU2015904022A0 (en) Implants for the Treatment of Diseases and Disorders

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069350

Country of ref document: HK